Predict continues share buyback as it expands innovative med-tech footprint

An update from Predict S.P.A. Class B ( (IT:PRE) ) is now available.

Predict S.p.A., an Italian med-tech SME specializing in diagnostic imaging, breath analysis technology and digital healthcare, has built a portfolio of in-house solutions such as the Mistral breath-analysis platform, the Aphel AI robotics system and the Optip holopresence solution, supported by partnerships with leading Italian university hospitals and research centers. The company, listed on Euronext Growth, has expanded its presence with offices in Bari and Milan, reinforcing its position in innovative healthcare technologies.

Predict has disclosed that it repurchased 6,000 treasury shares between 23 and 27 March 2026 at a weighted average price of €0.87 per share, for a total of €5,220, under its ongoing share buyback program authorized in 2025. Following these transactions, Predict holds 48,000 treasury shares, equal to 0.618% of its share capital, signaling continued execution of its capital management strategy while maintaining compliance with regulatory requirements.

The most recent analyst rating on (IT:PRE) stock is a Buy with a EUR1.45 price target. To see the full list of analyst forecasts on Predict S.P.A. Class B stock, see the IT:PRE Stock Forecast page.

More about Predict S.P.A. Class B

Predict S.p.A., founded in 2008 in Bari, is an innovative Italian med-tech SME focused on in vivo diagnostics, breath analysis and digital healthcare solutions. The company operates four strategic business units covering diagnostic imaging support, breath-based diagnostic technologies and augmented reality and robotics tools for medical professionals, and it collaborates with major university hospitals and research institutes across Italy.

Average Trading Volume: 26,890

Technical Sentiment Signal: Hold

Current Market Cap: €5.91M

For a thorough assessment of PRE stock, go to TipRanks’ Stock Analysis page.